.jpg)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Fibrocell Science Inc (NASDAQ: FCSC) today and set a price target of $22. The company’s shares closed yesterday at $2.34, close to its 52-week low of $2.21.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -10.9% and a 34.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Fibrocell Science Inc has an analyst consensus of Moderate Buy, with a price target consensus of $22.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.18 and a one-year low of $2.21. Currently, Fibrocell Science Inc has an average volume of 683.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fibrocell Science, Inc. is an autologous cell and gene therapy company, which engages in translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Its clinical and pre-clinical programs include treatments for restrictive burn scars, vocal cord scars, and acne scars.
